What is Spero Therapeutics, Inc.'s (SPRO) StockRank?

MoatMap's StockRank for Spero Therapeutics, Inc. (SPRO) is 80/100, with a Strong Buy signal. This is a composite score combining Quality (73), Value (59), and Momentum (41) factor ranks across MoatMap's 20,000+ stock universe.

Does Spero Therapeutics, Inc. have an economic moat?

Spero Therapeutics, Inc. (SPRO) has a Quality factor score of 73/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Spero Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Spero Therapeutics, Inc. (SPRO) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Spero Therapeutics, Inc. in?

Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SPRO

STRONG BUY

Spero Therapeutics, Inc. · Healthcare · United States · $131M · Avg Vol: $3M/d

StockRank

Get insider-trade alerts

P/E (TTM)

8.2x

ROE

35.1%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing novel antibiotics for multi-drug resistant bacterial infections. The company's lead product candidates aim to address serious unmet medical needs in conditions like complicated urinary tract infections and hospital-acquired pneumonia. Its dedication to combating antibiotic resistance positions Spero in a critical, high-barrier-to-entry niche within the pharmaceutical industry, addressing a global public health crisis.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR	TTM
Revenue	—	48.6M	96.7M	27.4M	59.6M	7.1%	61.2M
EPS	—	-1.23	0.43	-1.27	0.15	-40.9%	0.26
Shares	—	52.5M	53.0M	54.6M	56.4M	+7.5%	57.9M
Debt	—	6.6M	5.5M	4.3M	2.9M	-24.2%	2.5M
Equity	—	75.9M	106.9M	46.1M	59.0M	-8.1%	—
Op CF	—	-7.7M	-33.0M	-23.4M	-12.6M	—	7.2M
Inv CF	7.7M	33.8M	0	—	—	—	—
Fin CF	84.0M	-29.6M	0.2M	0	—	—	—

Loading 1Y...

PRICE (1Y)-27.6%

SMA 50SMA 200

$2.12

RSI (14)

50.6

52W High

$3.22

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

11.9%79.0

ROE

35.1%95.1

GP/Assets

48.5%86.1

Op. Margin

-2921.7%4.4

FCF/Assets

19.2%95.5

Piotroski

558.6

Int. Cover

—N/A

D/E Ratio

0.05x75.1

Current Ratio

10.50x87.8

Value

P/E (TTM)

8.2x92.6

EV/EBITDA

—N/A

P/FCF

9.9x84.5

P/B

2.3x53.8

P/S

2.0x67.7

Div Yield

—N/A

Momentum

52W High %

66%44.3

RS 6M

-25%39.5

SMA 50/200

1.05x75.3

EPS Rev 4W

0.0%64.0

EPS Rev 12W

—N/A

EPS Improve

-527%0.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$131M

P/E (Forward)

-1.9x

Gross Margin

54.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SPRO	Spero Therapeutics, Inc.(you)	$131M	80	STRONG BUY
NAGE	Niagen Bioscience, Inc.	$272M	75	BUY
ORMP	Oramed Pharmaceuticals Inc.	$191M	57	HOLD
CSBR	Champions Oncology, Inc.	$92M	54	HOLD
MDXG	MiMedx Group, Inc.	$585M	77	BUY
ABEO	Abeona Therapeutics Inc.	$320M	64	HOLD
FBIO	Fortress Biotech, Inc.	$92M	49	HOLD
PBYI	Puma Biotechnology, Inc.	$413M	98	STRONG BUY
ABUS	Arbutus Biopharma Corporation	$905M	84	STRONG BUY
DTIL	Precision BioSciences, Inc.	$188M	44	HOLD

Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%

Spero Therapeutics, Inc. (SPRO) — Stock Score Summary

Spero Therapeutics, Inc. (SPRO) has a MoatMap StockRank of 80/100 based on Quality (73/100), Value (59/100), and Momentum (41/100) factor scores. The current signal is STRONG BUY.

Key Financial Metrics

Price	$2.12
Market Cap	$131M
P/E (TTM)	8.15
P/E (Forward)	-1.91
Price/Book	2.32
Return on Equity	35.1%
Return on Invested Capital	11.9%
Debt/Equity	4.67
Gross Margin	54.6%
Operating Margin	-2921.7%
Revenue Growth	-95.6%
Free Cash Flow	$13M

Spero Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Spero Therapeutics, Inc.’s (SPRO) StockRank?: MoatMap’s StockRank for Spero Therapeutics, Inc. (SPRO) is 80/100, with a Strong Buy signal. It is a composite of Quality (73), Value (59), and Momentum (41) factor ranks across MoatMap’s 20,000+ stock universe.
Does Spero Therapeutics, Inc. have an economic moat?: Spero Therapeutics, Inc. (SPRO) has a Quality factor score of 73/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Spero Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Spero Therapeutics, Inc. (SPRO) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Spero Therapeutics, Inc. in?: Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).